Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The ...

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

Researchers found the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third ...

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in HR+ HER2-ve Breast ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.